CRANBURY, N.J.--(BUSINESS WIRE)--March 14, 2006--Valera Pharmaceuticals (NASDAQ:VLRX) today announced that Paladin Labs (TSX:PLB) received approval from Health Canada to market VANTAS(R), a 12-month implant developed by Valera for the palliative treatment of advanced prostate cancer. Valera previously received regulatory approval to commercialize VANTAS for this indication in the U.S. in late 2004 and in Denmark in November 2005. Valera recently reported that in 2005, the first full year of VANTAS sales in the U.S. reached $26.8 million.
